T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.81B |
| 2 |
XYZ
Block Inc
XYZ
|
+$1.46B |
| 3 |
Accenture
ACN
|
+$1.23B |
| 4 |
Gilead Sciences
GILD
|
+$1.15B |
| 5 |
Valero Energy
VLO
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.61B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.06B |
| 3 |
Tesla
TSLA
|
+$1.81B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.72B |
| 5 |
Amazon
AMZN
|
+$1.59B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.44% |
| 2 | Healthcare | 13.92% |
| 3 | Financials | 12.3% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BRKL
1926
DELISTED
Brookline Bancorp
BRKL
| $1.04M | ﹤0.01% |
95,376
+3,475
| +4% | +$40.5K |
|
1927
Trinity Capital Inc.
TRIN
$1.75B
| $1.04M | ﹤0.01% |
68,524
-127,000
| -65% | -$1.97M |
|
1928
First Financial Corp
THFF
$970M
| $1.03M | ﹤0.01% |
21,082
+701
| +3% | +$34.5K |
|
1929
Collegium Pharmaceutical
COLL
$913M
| $1.03M | ﹤0.01% |
34,538
+1,400
| +4% | +$42.8K |
|
|
FARO
1930
DELISTED
Faro Technologies
FARO
| $1.03M | ﹤0.01% |
37,750
+621
| +2% | +$18.2K |
|
1931
Navient
NAVI
$829M
| $1.03M | ﹤0.01% |
81,543
+1,583
| +2% | +$21.6K |
|
|
VISN
1932
Vistance Networks Inc
VISN
$2.67B
| $1.02M | ﹤0.01% |
192,934
-7,624
| -4% | -$40.5K |
|
1933
Trupanion
TRUP
$1.33B
| $1.02M | ﹤0.01% |
27,490
+14,516
| +112% | +$604K |
|
1934
G-III Apparel Group
GIII
$1.41B
| $1.02M | ﹤0.01% |
37,270
+1,705
| +5% | +$49.5K |
|
1935
Artivion
AORT
$1.39B
| $1.02M | ﹤0.01% |
41,300
+1,811
| +5% | +$50.3K |
|
1936
Annexon
ANNX
$873M
| $1.01M | ﹤0.01% |
524,741
-579,644
| -52% | -$1.93M |
|
1937
Universal Technical Institute
UTI
$1.41B
| $1.01M | ﹤0.01% |
39,448
+4,454
| +13% | +$120K |
|
1938
MannKind Corp
MNKD
$1.24B
| $1.01M | ﹤0.01% |
201,317
+26,308
| +15% | +$147K |
|
1939
Tandem Diabetes Care
TNDM
$1.63B
| $1.01M | ﹤0.01% |
52,843
+2,103
| +4% | +$61.5K |
|
|
MFA
1940
MFA Financial
MFA
$925M
| $1.01M | ﹤0.01% |
98,423
+4,669
| +5% | +$48.9K |
|
1941
BioCryst Pharmaceuticals
BCRX
$2.71B
| $1.01M | ﹤0.01% |
134,295
+7,489
| +6% | +$60.4K |
|
1942
Pennant Group
PNTG
$1.34B
| $1M | ﹤0.01% |
39,913
+3,967
| +11% | +$101K |
|
1943
Root
ROOT
$748M
| $1M | ﹤0.01% |
7,522
+1,782
| +31% | +$204K |
|
|
CSR
1944
Centerspace
CSR
$925M
| $1M | ﹤0.01% |
15,467
+715
| +5% | +$45.1K |
|
1945
Immuneering
IMRX
$328M
| $1M | ﹤0.01% |
659,009
-108,115
| -14% | -$196K |
|
1946
NeoGenomics
NEO
$2.11B
| $997K | ﹤0.01% |
104,962
+13,388
| +15% | +$167K |
|
1947
Wolverine World Wide
WWW
$1.63B
| $995K | ﹤0.01% |
71,481
+6,318
| +10% | +$115K |
|
1948
Par Pacific Holdings
PARR
$4.12B
| $994K | ﹤0.01% |
69,644
+9,832
| +16% | +$154K |
|
1949
Harmony Biosciences
HRMY
$2.32B
| $991K | ﹤0.01% |
29,839
+10,051
| +51% | +$360K |
|
|
MRC
1950
DELISTED
MRC Global
MRC
| $981K | ﹤0.01% |
85,398
+4,094
| +5% | +$52.9K |
|
Similar funds
T. Rowe Price Associates's Q1 2025 Portfolio in Review
As of Q1 2025, T. Rowe Price Associates held 3,109 positions worth $812B, down 6.4% from $867B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2025 filing shows 91 new, 2,002 increased, 738 reduced and 70 closed positions. Its largest new stake was T. Rowe Price Value ETF: 8,943,567 shares worth $283M. The largest sale was NVIDIA, an estimated $4.61B.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2025 buy was T. Rowe Price Value ETF: 8,943,567 shares worth $283M.
- T. Rowe Price Associates added most to Broadcom in Q1 2025, an estimated $3.81B increase.
- T. Rowe Price Associates's biggest Q1 2025 reduction was NVIDIA, cutting an estimated $4.61B.
- T. Rowe Price Associates fully exited Summit Materials, Inc. Class A Common Stock in Q1 2025, selling an estimated $271M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $812B portfolio in Q1 2025.
- T. Rowe Price Associates opened 91 new positions and closed 70 in Q1 2025.
- T. Rowe Price Associates's portfolio value fell 6.4% quarter-over-quarter to $812B.
Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.